1. Home /
    2. Altai Protocol Library /
  2. New Indication: Asciminib for CML

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Indication: Asciminib for CML

New Indication: Asciminib for CML
Study:
  • Phase 1, dose-escalation study
  • Refractory CML pts with prior at least two ATP-competitive TKIs
  • Asciminib once or twice daily (10 to 200 mg)
Efficacy:
  • 34 (92%) with a hematologic relapse => complete hematologic response
  • 31 (54%) without a complete cytogenetic response => complete cytogenetic response
  • 12 months major molecular response => 48%
  • 12 months major molecular response with T315I mutation =>28%
  • Ongoing molecular response 40/44 patients
Safety:
  • Grade >=3 AEs: All 60%. Lipase increased 10%, thrombocytopenia 9.3%, hypertension 9.3%, neutropenia 7.3%, anemia 7.3%.

N Engl J Med 2019; 381:2315-2326

Hughes TP., et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

https://doi.org/10.1056/nejmoa1902328

Reviewed by Hasan Cagri Yildirim, MD on Sep 30, 2021

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More